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Introduction
Mycobacterium tuberculosis (Mtb) infects one-third of  humans and causes almost 1.3 million deaths per year 
(1). Approximately 90% of  infected persons have latent tuberculosis infection (LTBI) and remain well, but 
10% develop primary tuberculosis (TB) soon after infection or reactivation of  TB many years later (2, 3). 
Nevertheless, only a small percentage of  persons with LTBI develop TB and therefore are required to com-
plete treatment regimens; approximately 13%–42% of  individuals prescribed treatment, fail to complete 
therapy (4, 5). The identification of  persons with LTBI who are at greatly increased risk of  development 
of  TB would be a significant breakthrough that would allow public health resources to be focused on high-
risk individuals, facilitate the completion of  therapy for LTBI, and prevent the future development of  TB. 
Severe immunosuppression due to HIV infection and treatment with corticosteroids and anti-TNF blockers 
markedly increase the risk of  the progression of  LTBI to active TB (6–9). Among persons who are not clin-
ically immunocompromised, limited information is available about other immune mechanisms that favor 
the progression of  LTBI to TB (10–21).
The household contacts (HHCs) of  TB patients are at high risk of  developing latent Mtb infection or 
active TB disease (22, 23). Identifying the HHCs that are likely to develop active TB is important to control 
TB (24–26). Examination of  HHCs is a natural method to study active TB disease development in a real-
time manner and to explore the early immune components involved in protection against TB. However, a 
detailed follow-up study and mechanistic understanding are important to identify the healthy HHCs of  TB 
patients who are at high risk.
In the current study, we followed 839 household contacts (HHCs) of tuberculosis (TB) patients for 2 
years and identified the factors that enhanced the development of TB. Fourteen of the 17 HHCs who 
progressed to TB were in the 15- to 30-year-old age group. At baseline (the “0“ time point, when all 
the individuals were healthy), the concentration of the thyroid hormone thyroxine (T4) was lower, 
and there were increased numbers of Tregs in PBMCs of TB progressors. At baseline, PBMCs from  
TB progressors stimulated with early secretory antigenic target 6 (ESAT-6) and 10 kDa culture filtrate 
antigen (CFP-10) produced less IL-1α. Thyroid hormones inhibited Mycobacterium tuberculosis 
(Mtb) growth in macrophages in an IL-1α–dependent manner. Mtb-infected Thra1PV/+ (mutant 
thyroid hormone receptor) mice had increased mortality and reduced IL-1α production. Our findings 
suggest that young HHCs who exhibit decreased production of thyroid hormones are at high risk of 
developing active TB disease.
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Immune responses mediated by antigen-presenting cells, NK cells, and T cells play an important role in 
the control of  Mtb infection (27). This is partly achieved through the production of  cytokines such as IL-1α, 
TNF-α, IFN-γ, and IL-1β in the lungs of  Mtb-infected mice and independently required for host resistance 
(28). TNF-α–mediated signaling is critical for reactive nitrogen production in macrophages and protection 
against Mtb (29). IFN-γ induces macrophage activation and controls growth of  intracellular pathogens.
Previous studies have demonstrated that monocytes, NK cells, innate lymphoid cells, and Tregs have 
the potential to contribute to innate and adaptive immune responses during Mtb infection (30–33). Endo-
crine abnormalities such as adrenal insufficiency, diabetes mellitus, and calcium-vitamin D abnormalities 
are common in TB patients, suggesting that the endocrine system also plays an important role in the control 
of  Mtb infection (34–36). Hormones can affect immune cell function and induce the production of  inflam-
matory cytokines. In a rabbit Mtb infection model, it was shown that defective thyroid hormone production 
enhances susceptibility to Mtb infection (37). However, it is not known whether defective hormone produc-
tion leads to the development of  active TB disease in HHCs of  TB patients.
In the current study, we evaluated the phenotype and function of  various immune cells and other fac-
tors, such as hormones, in a large group of  household contacts of  TB patients (a total of  839 individuals). 
We repeated these evaluations at 24 months while monitoring the subjects for the development of  active 
TB. By following a large cohort of  HHCs of  TB patients, we determined whether the development of  TB is 
preceded by specific changes in the cellular markers of  immune cells and other factors. We also confirmed 
our findings using a mouse model of  Mtb infection.
Results
Demographic characteristics of  the cohort. Among the 839 individuals enrolled, we had 83.5% retention, and 
138 individuals were lost to follow-up. The median number of  HHCs per index case was 3. Fifty-nine 
percent of  the HHCs were LTBI-positive at baseline, and 2.53% of  the HHCs progressed to active TB 
disease during follow-up. Among the 839 HHCs, 465 (56%) were 15–30 years old, 228 (27%) were 31–44 
years old, and 146 (17%) were 45–73 years old (Table 1). Demographic and clinical characteristics of  the 
study participants are shown in Table 1. The summaries of  screening, enrollment, and loss to follow-up are 
shown in Supplemental Tables 1 and 2; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.148271DS1.
The prevalence of  TB was high in young HHCs. During the 2-year follow-up period, 688 HHCs success-
fully completed the study. Seventeen (2.53%) out of  688 HHCs developed active TB (progressors), and 
671 of  the HHCs remained healthy (nonprogressors) (Figure 1 and Table 1). Among the 17 progressors, 
14 (82.35%) were in the 15–30-year-old age group, 2 (11.8%) were in the 31–44-year-old age group, and 
1 (5.9%) was in the 45–73-year-old age group (Supplemental Table 3). In summary, young HHCs of  TB 
index cases were at increased risk of  developing active TB (relative risk, 3.75; 95% CI, 1.086 to 12.96; P 
= 0.036). The demographic and clinical characteristics of  the HHCs that developed active TB during the 
2-year study are shown in Supplemental Table 3. The complete blood cell counts of  the progressors and 
nonprogressors are shown in Supplemental Figure 1.
High CD16+CD56+ and Treg cell frequencies in progressors at baseline. We determined the percentages of  vari-
ous immune cell populations in freshly isolated PBMCs of  subsets of  nonprogressors (n = 87) and progressors 
(n = 12) at baseline and during the follow-up visits. The frequencies of  CD14+ (P = NS, Figure 2A and Sup-
plemental Figure 2) and CD14+CD16+ cells (P = NS, Figure 2B and Supplemental Figure 2) were similar at 
baseline in the progressors compared with the nonprogressors. The percentages of  CD16+CD56+ cells were 
higher at baseline in the progressors than in the nonprogressors (P = 0.035; Figure 2C and Supplemental 
Figure 2). Interestingly, there was a 2.5-fold decrease in the percentage of  CD16+CD56+ cells (P = 0.0006; 
Figure 2C) in the progressors at follow-up (blood was obtained when they developed active TB) compared 
with the baseline values. The percentages of  CD4+CD25+FoxP3+ cells (Tregs) were significantly higher in the 
progressors at baseline (P = 0.048) and follow-up (P = 0.047; Figure 2H and Supplemental Figure 2) than in 
nonprogressors. No significant differences were observed in percentages of  NK cells and T cells in progressors 
compared to nonprogressors (Figure 2, D–G).
Reduced IL-1α production by PBMCs in progressors at baseline. We determined cytokine and chemokine pro-
duction by freshly isolated PBMCs from progressors (n = 12) and nonprogressors (n = 12) cultured in the 
presence and absence of  the Mtb antigens early secretory antigenic target 6 (ESAT-6) and culture filtrate 
antigen (CFP-10), as mentioned in the Methods. Among 34 cytokines and chemokines tested, as shown in 
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Figure 3 and Supplemental Figure 3, at baseline, the production of  IFN-γ, IL-13, IL-10, and IL-18 was higher 
in the culture supernatants of  the progressors than the nonprogressors (P < 0.05, Figure 3). In contrast, IL-1α 
(P = 0.047; Figure 3) levels were significantly lower in the culture supernatants of  the progressors compared 
with the supernatants of  the nonprogressors. At follow-up, IFN-γ (P = 0.09), IL-17, IL-22, IL-23, and IL-1α 
(P < 0.05) levels were lower in the progressors than in nonprogressors (Figure 3 and Supplemental Figure 3).
Lower hormone levels in the progressors at baseline. The findings in Supplemental Table 3 indicated that 14 
out of  the 17 HHCs who developed active TB disease were in the 15- to 30-year-old age group. Given that 
hormones play an important role in growth, metabolism, and immunity (38), we determined the levels of  
various serum hormones in the progressors and nonprogressors (both in the same age group) at baseline 
(Figure 4 and Supplemental Figure 4). Serum dehydroepiandrosterone (DHEA), cortisol, and thyroid stim-
ulating hormone (TSH) levels were similar in progressors and nonprogressors at baseline (Supplemental 
Figure 4). As shown in Figure 4B, at baseline, the level of  thyroxine (T4) hormone (P = 0.0002) was signifi-
cantly lower in the serum of  the progressors compared with the nonprogressors (relative risk, 7.3; 95% CI, 
3.09 to 17.35; P = 0.0001). There was a further decrease in the T4 levels during TB activation (P = 0.003) 
compared with baseline. After standard antitubercular treatment (ATT), serum triiodothyronine (T3) and 
T4 significantly increased in progressors (Figure 4, A and B). However, 3 years after ATT, the level of  T4 
hormones significantly decreased in treated progressors (Figure 4B). The diagnostic accuracies of  various 
hormones were evaluated by receiver operating characteristic (ROC) curve analysis to distinguish progres-
sors and nonprogressors at baseline. ROC curve analysis revealed that among all the measured hormones, 
baseline T4 (AUC > 0.86) and DHEA levels (AUC > 0.78) could distinguish between nonprogressor and 
progressor HHCs, with a high AUC value (Figure 4C and Supplemental Figure 5, A–C).
Monocytes/monocyte-derived macrophages upregulate thyroid hormone receptors in response to γ-Mtb stimulation. 
We determined the expression of  thyroid (TR1α and TR1β) and steroid hormone receptors (glucocorti-
coid receptor [GR1]) by various immune cell populations within freshly isolated PBMCs before and after 
stimulation with γ-irradiated Mtb (γ-Mtb). As shown in Figure 5, A and B and Supplemental Figure 8, 
TR1α, TR1β, and glucocorticoid receptor expression were significantly higher in monocytes than in NK, 
T, NKT, and B cells from fresh PBMCs. γ-Mtb significantly enhanced TR1α, TR1β, and glucocorticoid 
receptor expression by macrophages compared with NK cells, B cells, and T cells (Figure 5, A and B, and 
Supplemental Figures 6–8). In γ-Mtb–stimulated PBMCs, we also found higher expression of  TR1α on NK 
and T cells compared with unstimulated PBMCs (Figure 5A). Further, Mtb H37Rv infection enhanced the 
Table 1. Demographic characteristics of the cohort.
Characteristics N (%)
Cohort size 839
Median age (years) 28 (15–73)












Screening history Chest x-rays obtainedHIV test obtained
15
839
Outcome group Completed studyLost to follow-up
701
138
BCG vaccination (percentage) 579 (69%) — vaccination
Prevalence of latent TB infection in the cohort 495 (59%)
Active TB converters 17 (2.53%)
Median/mean size of the household 3
HIV prevalence in cohort (percentage) N =1 (0.12%)
Other comorbidities None
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expression of  thyroid hormone receptor TRα1/β1 complex on human monocytes/monocyte-derived mac-
rophages (MDMs) (P < 0.0001, Figure 6, B and C). Deiodinase (DIO) type 2 (D2) converts prohormone T4 
into the active hormone T3 in macrophages and plays a crucial role in cytokine production and phagocyto-
sis (39, 40). Control and Mtb H37Rv–infected human MDMs expressed DIO 1, 2, and 3, as determined by 
Western immunoblotting (Supplemental Figure 9).
T3 and T4 hormones restrict Mtb growth in human MDMs. We determined the effects of  thyroid and steroid 
hormones on intracellular mycobacterial growth in MDMs. Freshly prepared MDMs from 7 healthy indi-
viduals aged 18–30 years were infected with Mtb H37Rv at an MOI of  2.5 and cultured in the presence or 
absence of  various concentrations of  the hormones T3, T4, cortisol, and DHEA. After 120 hours, 4.6 × 105 ± 
0.54 × 105 CFUs per well of  untreated MDMs were present. Addition of  T3 (15 nmol/L) and T4 (150 nmo-
l/L) hormones significantly reduced the number of  CFUs in the MDMs (from 4.6 × 105 ± 0.54 × 105 to 6.7 
× 104 ± 0.21 × 104, P < 0.0001, for T3 and 1.7 × 105 ± 0.76 × 105, P = 0.0006, for T4) (Figure 5C). However, 
supplementation with the cortisol and DHEA hormones had no effect on Mtb growth in MDMs (Figure 5C). 
The viability of  the hormone-treated and untreated MDMs was similar (Supplemental Figure 10). Our results 
demonstrated that thyroid hormones inhibited Mtb growth in MDMs more efficiently than steroid hormones.
Hormones enhance IL-1α production by Mtb-infected MDMs. To determine the mechanism(s) by which T3 
and T4 hormones inhibit Mtb growth in human MDMs, we measured various cytokine and chemokine 
levels in the culture supernatants of  Mtb-infected MDMs by multiplex ELISA. Freshly prepared MDMs 
from 5 healthy individuals from the 18- to 30-year-old age group were infected with Mtb H37Rv at an MOI 
of  2.5 and cultured in the presence or absence of  T3 (15 nmol/L) and T4 (150 nmol/L). Addition of  T3 
and T4 hormones to Mtb-infected MDMs enhanced the production of  IL-1α (P = 0.0008 in the presence 
or absence of  T3; P = 0.048 in the presence or absence of  T4) (Figure 6A and Supplemental Figure 11). 
We also confirmed the above findings with confocal microscopy, and the H37Rv-infected human MDMs 
produced more IL-1α in the presence of  the T4 hormone (Figure 6C).
Hormones inhibit Mtb growth in human MDMs through IL-1α production. Next, we determined whether T3 or 
T4 hormone–mediated IL-1α production restricts Mtb growth in human MDMs. Freshly prepared MDMs from 
6 healthy individuals aged 18–30 years were infected with Mtb H37Rv and cultured in the presence of T4 hor-
mone. Some of the T4 hormone–treated and untreated wells were treated with anti–IL-1α antibody. As shown 
in Figure 6D, after 120 hours, 4.1 × 105 ± 1.07 × 105 CFUs per well of untreated MDMs were present. Addition 
of T4 hormone reduced the number of CFUs to 1.2 × 105 ± 0.20 × 105 (P < 0.0001; Figure 6D). The addition 
of the anti–IL-1α antibody enhanced Mtb growth in T4 hormone–treated wells (1.2 × 105 ± 1.07 × 105 to 2.5 
× 105 ± 0.51 × 105 CFU, P = 0.03; Figure 6D). The treatment of Mtb-infected MDMs with recombinant IL-1α 
also restricted Mtb growth (from 3.8 × 105 ± 0.51 × 105 to 1.5 × 105 ± 0.72 × 105 CFUs, P = 0.004; Figure 6E).
Thra1PV/+ mice are susceptible to Mtb infection. To determine the role of  thyroid hormone signaling in Mtb 
infection, we infected WT and Thra1PV/+ mice expressing a dominant-negative thyroid receptor α1 mutant 
(TRα1PV) with Mtb H37Rv as described in the Methods (Supplemental Figure 12 and Figure 7A) (41). 
Figure 1. Study design and outcomes for the household contacts in the TB patient cohort study. Schematic representation of the experimental design.
5
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e148271  https://doi.org/10.1172/jci.insight.148271
Thra1PV/+ mice were dwarfs, and by 6 weeks of  age, the mean body weight of  Thra1PV/+ mice was 12.4 ± 
2.9 g, which was approximately 40% less than that of  their WT littermates (Supplemental Figure 13) (41). 
Mtb infection significantly reduced the weight of  Thra1PV/+ mice compared with that of  uninfected WT or 
Thra1PV/+ mice (Supplemental Figure 13). As shown in Figure 7B, by 65 days after infection, 44.5% of  the 
Mtb-infected Thra1PV/+ mice had died, whereas only 25% of  the uninfected Thra1PV+ mice had died. In con-
trast, all WT-infected or uninfected mice survived (Figure 7B). One month after Mtb infection, there was a 
significant increase in the number of  CFUs of  bacteria in the lungs of  Thra1PV+ mice compared with WT 
mice infected with Mtb (1.8 × 106 ± 0.22 × 106 vs. 0.45 × 106 ± 0.047 × 106 CFUs, P = 0.0004, Figure 7C).
Mtb-infected Thra1PV/+ mice have defective immune responses. We asked whether lack of  thyroid hormone 
signaling had any effect on immune responses during Mtb infection. WT and Thra1PV/+ mice were infected 
with Mtb, and after 1 month the levels of  various cytokines and chemokines were measured in lung homog-
enates by multiplex (34-plex) ELISA. As shown in Figure 7D and Supplemental Figure 14, levels of  inflam-
matory cytokines IFN-γ and IL-1α and chemokines IP-10, MIP-1α, MCP-3, and MIP-1β were significantly 
lower in whole lung homogenates of  Mtb-infected Thra1PV/+ mice than in homogenates of  Mtb-infected 
WT mice (Figure 7D). We also examined various leukocyte populations by flow cytometry. The absolute 
numbers of  total CD45+ and CD45+F4/80+ cells were significantly lower, whereas the numbers of  Tregs 
(CD4+CD25+FoxP3) and CD45+CD11c+ cells were significantly higher at 1 month after Mtb infection in 
the lungs of  Mtb-infected Thra1PV/+ mice than in Mtb-infected WT control or uninfected Thra1PV/+ mice 
(Figure 7E and Supplemental Figures 15 and 16). Histological analysis revealed that the number of  lesions 
throughout the lungs was significantly higher in the lungs of  Mtb-infected Thra1PV/+ mice than in Mtb-in-
fected WT mice or uninfected Thra1PV/+ mice (Figure 7, F and G).
Discussion
In the current study, we followed 839 healthy HHCs of  TB patients for 2 years, obtained blood samples at 
4-month intervals, and determined various factors correlated with the development of  active TB in some 
of  the HHCs. During the 24-month follow-up period, 17 HHCs developed active TB, and 14 (82.4%) of  
Figure 2. Immune cell distribution in the PBMCs of household contacts of TB patients. PBMCs were isolated from age-matched non-TB progressors (n = 
87) and TB progressors (n = 12) at baseline and follow-up (when the progressors were registered as having active TB), and the percentages of (A) CD14+, (B) 
CD14+CD16+, (C) CD16+CD56+, (D) CD3–CD56+, (E) CD3–CD56+CD27+CCR7+, (F) CD3+, (G) CD4+, and (H) CD4+CD25+FoxP3+ cells were determined by flow cytome-
try. The data from 87 nonprogressors and 12 progressors are shown. All the age-matched, non-TB progressors were healthy, nonsmoking, and nonalcoholic 
and were without any immunosuppressive conditions at baseline or follow-up. Data from smoking and alcoholic progressors were not included. P values 
were determined using 1-way ANOVA with Tukey’s multiple-comparison test. The mean ± SEM and P values are shown.
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these progressors were in the 15- to 30-year age group. This suggests that the development of  active TB in 
HHCs is age-dependent (relative risk, 3.75). At baseline (the “0” time point, when all the individuals were 
healthy), levels of  circulating thyroid hormone T4 were significantly lower in the progressors compared 
with age-matched nonprogressors. At baseline and follow-up (a blood sample was obtained when active TB 
developed), freshly isolated PBMCs of  the progressors had more CD16+CD56+ cells and Tregs than non-
progressors. At baseline, ESAT-6– and CFP-10–stimulated PBMCs of  progressors produced more IFN-γ, 
IL-13, IL-10, and IL-18 and less IL-1α compared with ESAT-6– and CFP-10–stimulated PBMCs of  non-
progressors. In the presence of  thyroid hormones T3 and T4, monocytes significantly inhibited Mtb growth 
in human MDMs in an IL-1α–dependent manner. We also found that Thra1PV/+ mice (with defective thy-
roid hormone signaling) were more susceptible to Mtb infection than WT mice. Our studies identified 
additional risk factors for the development of  active TB in the healthy HHCs of  TB patients.
The HHCs of  TB patients in developing countries are at an increased risk of  development of  active TB 
(25). It is known that this risk is further enhanced by HIV infection, alcoholism, smoking, diabetes, and 
other immunosuppressive conditions (42–45). However, there is limited information about the risk factors 
that enhance the development of  active TB in healthy HHCs (10–21). Age is a major factor associated with 
Mtb infection (46). Children are at an increased risk of  TB infection and disease progression because of  their 
immature immune system (47, 48). Similarly, the geriatric population represents a large reservoir of  LTBI and 
is at high risk of  developing active disease because of  a weak immune system (49, 50). In the current study, 
we found that adolescents could be at risk for development of  TB and that there was a correlation between 
decreased circulating thyroid hormone T4 levels in the progressors compared with age-matched nonprogres-
sors. Hormones can directly affect the activity of  immune cells and control inflammatory, autoimmune, or 
infectious immune responses (51, 52). The bidirectional communication between the neuroendocrine and 
immune systems is well established (53). Glucocorticoids can inhibit Th1 responses, whereas their natural 
antagonist DHEA is able to promote such responses (54). TB patients have altered thyroid hormone and 
Figure 3. Cytokine and chemokine profiles of ESAT-6– and CFP-10–stimulated PBMCs. PBMCs from nonprogressors (n = 12) and progressors (n = 12) at baseline 
and follow-up were isolated and cultured with or without ESAT-6 and CFP-10 (10 μg/mL each), as described in Methods. After 96 hours, the culture supernatants 
were collected, and levels of various chemokines and cytokines were measured by multiplex ELISA. All the age-matched non-TB progressors were healthy, non-
smoking, and nonalcoholic and were without any immunosuppressive conditions at baseline and follow-up. Data from smoking and alcoholic progressors were 
not included. P values were determined using 1-way ANOVA with Tukey’s multiple-comparison test. The mean values, SEM, and P values are shown.
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DHEA levels (55). In inbred rabbits, administration of  T3 or T4 hormone markedly increased resistance to 
Mtb infection and hypothyroidism enhanced the susceptibility to Mtb infection (56). In the current study, 
HHCs who developed active TB disease during the follow-up period had a low level of  serum T4 at baseline 
(Figure 4). TSH levels are regulated by T4 hormone through a negative feedback loop (57). However, our 
study found similar levels of  TSH in nonprogressors and progressors at baseline (Supplemental Figure 4C). 
Our study demonstrated, to our knowledge, that decreased circulating T4 hormone levels at baseline can be a 
risk factor for young adult HHCs of  TB patients.
At baseline, ESAT-6– and CFP-10–stimulated PBMCs of  progressors produced less IL-1α than the 
stimulated PBMCs of  the nonprogressors (Figure 3). IL-1α–deficient mice are susceptible to infection with 
low-dose aerosolized Mtb (58). Furthermore, in vivo neutralization of  IL-1α renders mice highly suscepti-
ble to Mtb, and IL-1α is essential for the establishment of  host resistance to Mtb. Chronic Mtb infection in 
IL-1α knockout mice causes large and diffuse inflammatory lesions in the lungs and the dispersed distribu-
tion of  Mtb-infected cells (58). This suggests the important role of  IL-1α–driven cell-cell crosstalk in coor-
dinating protective granuloma formation or maintenance (58, 59). Our study demonstrated a correlation 
between decreased IL-1α production at baseline and the development of  active TB disease at follow-up.
We found that monocytes are the major cell population that express thyroid and glucocorticoid recep-
tors. T3 and T4 but not cortisol and DHEA enhanced IL-1α production by Mtb-infected macrophages and 
inhibited Mtb growth in an IL-1α–dependent manner. Thyroid receptor-α expression on macrophages mod-
ulates the inflammation caused by infection (60). Thyroid hormone–treated macrophages display the M1 
phenotype and show improved capacity for phagocytosis (60). We have not determined the IL-1α–depen-
dent mechanisms that inhibit Mtb growth in macrophages. However, it is known that IL-1 signaling inhibits 
Mtb growth in a COX2-dependent manner by suppressing IFN-1 production (58). In the current study, we 
found that young HHCs with reduced circulating T4 levels develop active TB and found a mechanism by 
which the T3 and T4 hormones inhibited Mtb growth in an IL-1α–dependent manner.
In addition to the above findings, we also found higher numbers of  CD16+CD56+ cells and Tregs in 
fresh PBMCs; increased IFN-γ, IL-13, and IL-10 production; and reduced IL-1α production by the ESAT-
6– and CFP-10–stimulated PBMCs of  progressors compared with nonprogressors at baseline. NK cells are 
Figure 4. Hormone levels in the serum of HHCs of TB patients. Serum (A) T3 and (B) T4 hormone levels of the nonprogressors (n = 67) and progressors  
(n = 12) at baseline and follow-up (at TB activation) were quantified by ELISA. All the age-matched nonprogressors were healthy, nonsmoking, and nonal-
coholic and were without any immunosuppressive conditions at baseline or at follow-up. Data from smoking and alcoholic progressors were not included. 
P values were derived using an unpaired, 2-tailed, independent t test. Mean ± SD and P values are shown. (C) The receiver operating characteristic (ROC) 
curve for the hormone T4; plot shows the ROC curve for T4 hormone levels in nonprogressors (n = 67) and TB progressors (n = 12) at baseline. The ROC 
curve shows the true-positive rate (sensitivity) and false-positive rate (1-specificity) of the model prediction. The biomarker analysis program in Metabo-
Analyst software was used to generate the ROC curves and calculate the AUC.
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Figure 5. Thyroid hormones restrict Mtb growth in vitro. Freshly isolated PBMCs from 5 healthy individuals (age range: 
18–30 years) were cultured with or without γ-irradiated Mtb H37Rv (γ-Mtb, 10 μg/mL) for 120 hours. (A) The percentages  
of TR1-α+ and (B) TR1-β+ cells among monocytes, NK cells, T cells, NKT cells, and B cells were determined by flow cytom-
etry. P values were determined using 1-way ANOVA with Tukey’s multiple-comparison test. The mean values, SD, and P 
values are shown. (C) Mtb growth in monocyte-derived macrophages (MDMs). The MDMs from healthy individuals (n = 
7) were infected with H37Rv at an MOI of 2.5 as described in Methods. Some of the infected MDMs were cultured in the 
presence of T3 (5, 10, 15 nmol/L), T4 (50, 100, 150 nmol/L), DHEA (200, 400, 800 μg/dl), or cortisol (200, 400, 800 nmol/L) 
for 5 days. The supernatant was aspirated, and the MDMs were lysed. Supernatant was centrifuged to pellet the bacteria, 
and the pellets were added to the cell lysates. The bacterial suspensions were ultrasonically dispersed, serially diluted, and 
plated in triplicate on 7H10 agar. The number of resultant colonies was counted after 3 weeks. The P values were derived 
using an unpaired, 2-tailed, independent t test. The mean values and SD are shown for the number of CFUs per well.
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an important component of  the innate immune response and kill Mtb-infected cells (61, 62). CD16 (Fc 
receptor γRIIIa) is a mediator of  antibody-dependent cell-mediated cytotoxicity and is expressed by a sub-
population of  NK cells (63). Antibody recognition by CD16 results in the activation of  NK cells, release of  
cytolytic granules, and the killing of  target cells (63). In the current study, we found that CD16-expressing 
NK cell numbers were high in the progressors at baseline compared with nonprogressors, and this number 
was reduced when HHCs developed active TB disease. We have not determined the function of  CD16+ 
NK cells in progressors and nonprogressors, but our study results are in accordance with those of  a recent 
cohort study that found lower numbers of  peripheral blood NK cells in patients with active TB, whereas 
individuals with LTBI had a normal NK cell number. Recent studies in nonhuman primates demonstrated 
that CD27+ NK cells accumulate more in the lung of  LTBI-positive macaques compared with macaques 
with active TB (64). This NK cell population was also detected in circulation of  LTBI-positive individuals 
and expanded in response to Mtb antigens (33).
At baseline and follow-up (at the time of the development of active disease), we found higher numbers of  
Tregs in the PBMCs of the progressors compared with those in the PBMCs of the nonprogressors. Activated 
CD4+ T cells can transiently express CD25 and FoxP3 (65), and we have not measured the suppressive function 
of CD4+CD25+FoxP3+ cells. It is possible that increased numbers of CD4+CD25+FoxP3+ cells in the PBMCs 
of the progressors may be due to increased activated CD4+ cells. ESAT-6– and CFP-10–stimulated PBMCs of  
progressors produced more IL-10 than the stimulated PBMCs of nonprogressors at baseline and at follow-up. 
Tregs produce IL-10 and play an important role in modulating Mtb-specific immune responses (66). Tregs in 
lymph nodes reduce the frequency of Mtb-responsive IFN-γ–producing CD4+ and CD8+ T cells, and there is 
an association between the number of Tregs and the severity of Mtb infection (31, 67). The higher preinfection 
frequencies of Treg cells in Mtb-infected cynomolgus macaques was associated with a higher likelihood of latent 
TB (68). Our study suggests that the increased numbers of Tregs along with increases in other markers at base-
line in young HHCs of TB patients can serve as a biomarker for the future development of active TB.
We found that the Mtb antigen–stimulated PBMCs of  the progressors produced more IFN-γ and IL-13 
than the stimulated PBMCs of  the nonprogressors at baseline. In contrast, the ESAT-6– and CFP-10–stim-
ulated PBMCs of  progressors produced less IFN-γ, IL-17, and IL-1α compared with the stimulated PBMCs 
of  the nonprogressors at follow-up (when the progressors developed active TB). The essential protective 
role of  these cytokines during Mtb infection is well known (69). The higher numbers of  CD56+CD16+ cells 
and higher levels of  protective cytokine production at baseline in the progressors suggest that strong host 
defense mechanisms are in place to protect the progressors during the early stages of  infection, but the fail-
ure of  these mechanisms leads to the development of  active TB disease. This failure was demonstrated by 
reduced numbers of  CD56+CD16+ cells and the production of  associated cytokines in progressors.
Similar to the above findings in humans, Mtb-infected Thra1PV/+ mice demonstrated defective effector 
cytokine (IL-1α and IFN-γ) and chemokine (IP-10, MIP-1α, MIP-1β, and MCP-3) production, a higher 
number of  Tregs, a higher bacterial burden in the lungs, and higher mortality than Mtb-infected WT mice 
(45.4% of  the mice died within 65 days, Figure 7). Thyroid hormone signaling can affect immune cell 
functions, such as chemotaxis, phagocytosis, ROS generation, cytokine production, and metabolism (70). 
Given that T4 and T3 play pleiotropic roles in metabolism, our findings with Thra1PV/+ mice may not be 
specific for Mtb infection and it is possible that Thra1PV/+ mice may be susceptible to other infections. Our 
human and mouse findings suggest that thyroid hormone signaling is essential for the generation of  opti-
mal immune responses during Mtb infection.
In summary, we followed a large number of healthy HHCs of TB patients, obtained blood samples at reg-
ular intervals, and identified the risk factors that enhanced the development of active TB. Our findings suggest 
that young HHCs of TB patients with increased numbers of CD16+CD56+ cells and Tregs as well as decreased 
production of T4 hormone and IL-1α at baseline are at an increased risk of developing active TB disease.
Methods
Human studies
Cohort description. Over 4 years, a total of 839 household contacts were enrolled in the study. The following were 
used as the enrollment criteria.
Index patients were newly diagnosed, sputum-positive pulmonary TB patients attending the Designated 
Microscopy Centers under TB clinics at Bhagwan Mahavir Medical Research Centre (BMMRC) and Blue Peter 
1 0
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e148271  https://doi.org/10.1172/jci.insight.148271
1 1
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e148271  https://doi.org/10.1172/jci.insight.148271
Public Health & Research Centre (BPHRC) in Hyderabad, India. Active TB diagnosis was performed by follow-
ing the Revised National Tuberculosis Control Programme (RNTCP) (now National Tuberculosis Elimination 
Programme, NTEP) guidelines.
Household members residing in the same house as the index case for a minimum of 3 months prior to the 
date of diagnosis of TB were identified. These individuals had shared at least 5 meals per week with the index 
case and had no past history of TB or ATT. The demographic details of the HHCs, including age, sex, history 
of Bacillus-Calmette-Guerin (BCG) vaccination, history of pulmonary TB, and smoking and drinking profiles, 
were collected and are shown in Table 1.
The exclusion criteria were HHCs having HIV, diabetes, autoimmune diseases, or any other immunosup-
pressive condition; children younger than 15 years were excluded. If  participants developed comorbid condi-
tions and started using tobacco (chewing tobacco or smoking) or alcohol (more than 2 drinks per week) during 
the study, their data were excluded from the final analysis.
Initial screening of  the participants. Prior to enrollment in the study, HHCs were screened to ensure that they 
meet the eligibility criteria outlined above. Screening evaluations included eligibility assessment, informed con-
sent, detailed medical history, and exposure assessment to the index case. Local laboratory evaluations to rule 
out HIV, diabetes, and any other chronic conditions were performed. After enrollment, baseline visits were 
scheduled and blood samples were collected. Demographics and data on smoking and alcohol usage were col-
lected. Physical examination was done and participants’ height and weight were noted. Blood samples were 
used to perform immune assays and hematological analysis. Participants were categorized as having LTBI by an 
in-house assay as outlined in the section below.
Latent TB in the study cohort. HHCs were categorized as LTBI-positive or LTBI-negative using an in-house 
interferon gamma release assay (IGRA) (Supplemental Data Set 1) (71). The test was performed every 4 months 
irrespective of baseline IGRA result. The HHCs with symptoms consistent with TB were evaluated by chest 
radiography and clinical evaluation. A complete blood panel was performed to study the hematological cor-
relates of the progression to TB as outlined in Supplemental Figure 1.
Follow-up of  HHCs. All HHCs were evaluated every 4 months for 2 years. At each visit, they were eval-
uated for TB, and 20 mL of blood was collected. Blood samples were used to perform immune assays and 
hematological analysis. An in-house assay was performed to identify LTBI converters and nonconverters (71). 
All participants with symptoms of  possible TB were referred for clinical evaluation and treatment.
Outcome determination. The outcomes of the study were as follows: 1) completion of the 2-year follow-up; 2) 
development of TB in some HHCs; and/or 3) withdrawal of the participants from the study.
Progressors were classified as those with signs and symptoms consistent with active TB and those with 1) 
clinical specimens that showed acid-fast bacilli in the test smear or Mtb in culture or 2) chest radiographic chang-
es consistent with TB and a clinical response to ATT. The nonprogressors were individuals who completed their 
follow-up without development of TB.
TB treatment in active TB progressors. Seventeen of  the HHCs progressed to active TB during the fol-
low-up. These HHCs were referred to the RNTCP (now NTEP) centers for treatment. All the TB pro-
gressors were screened for rifampicin resistance following RNTCP guidelines, and no drug resistance 
was observed in any of  them. Standard fixed-dose combination (FDC) first-line ATT was administered 
to the patients according to their weight bands. Treatment was administered daily for a minimum of  6 
months with 4 standard FDC drugs in the intensive phase and 3 drugs during the continuation phase. 
Although TB activation was an off-study criterion in this study, samples were collected from progressors 
after TB treatment for hormone assays.
Figure 6. Thyroid hormones induce IL-1α production by Mtb-infected monocytes/monocyte-derived macrophages. Freshly isolated monocytes/monocyte- 
derived macrophages (MDMs) from 18- to 30-year-old donors (n = 5) were infected with H37Rv at an MOI of 2.5, as described in Methods. Some of the infected 
MDMs were cultured in the presence of T3 (15 nmol/L) or T4 (150 nmol/L) for 5 days. (A) The supernatants were aspirated, and cytokine and chemokine produc-
tion were measured by multiplex ELISA. P values were derived using 1-way ANOVA with Tukey’s multiple-comparison test. The mean values, SD, and P values 
are shown. (B) The Mtb-infected MDMs in the presence or absence of T4 (150 nmol/L) were examined for TR-α1/β1 expression and IL-1α production by confocal 
microscopy. The images were taken at 63× magnification with oil immersion. Scale bar: 20 μm. (C) The respective immunofluorescence intensities are shown 
(n = 5). P values were derived using 1-way ANOVA with Tukey’s multiple-comparison test. Mean values, P values, and SD are shown. (D) Freshly prepared MDMs 
from 18- to 30-year-old donors (n = 6) were infected with H37Rv at an MOI of 2.5, as described in Methods. The infected MDMs were cultured in the presence of 
T4 (150 nmol/L), and the anti–IL-1α (10 μg/mL) antibody was added to some wells. The supernatant was aspirated; MDMs were lysed and plated on 7H10 agar. 
The number of colonies was counted after 3 weeks. The mean ± SD and P values are shown. The P values were determined using 1-way ANOVA with Tukey’s 
multiple-comparison test. (E) The MDMs (n = 5) were infected with H37Rv and cultured in the presence or absence of recombinant IL-1α (10 ng/mL); the number 
of bacterial colonies was determined. The P values were derived using an unpaired, 2-tailed, independent t test. Mean values and SD are shown.
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Determination of  LTBI in the HHCs. LTBI in the HHCs was determined according to our previously published 
protocols (71). A total of 2 × 106 human PBMCs were stimulated with and without 10 μg/mL CFP-10 and 
ESAT-6 antigens and incubated at 37°C for 96 hours. IFN-γ released by PBMCs was measured with a sandwich 
ELISA using a commercial human IFN-γ kit (eBioscience Inc.) by following the manufacturer’s instructions. 
The IFN-γ concentration was calculated using MPM software version 6.1. HHCs were categorized as either 
LTBI-negative or LTBI-positive depending on the IFN-γ value.
Complete blood count analysis. Whole blood collected in EDTA was subjected to complete blood count 
analysis by using an automated cell counter (Mindray Biochemistry Analyzer, Golden Harvest Industries). A 
total of  200 μL of the whole blood collected in an EDTA tube was used for the complete blood count analysis. 
The WBC, RBC, and platelet counts were determined by impedance method, and hemoglobin levels were 
determined by colorimetry.
Antibodies and other reagents. PE anti-CD16 (catalog 555407), PerCP anti-CD14 (catalog 340585), and APC 
anti-CD56 (catalog 555518) were used to identify monocytes and NK cells. FITC anti-CCR7 (catalog 561271), 
PE anti-CD27 (catalog 555441), PerCP anti-CD3 (catalog 555332), and APC anti-CD56 (catalog 555518) were 
used to identify the T cell and NK cell populations. FITC anti-CD4 (catalog 555346), PE anti-Foxp3 (catalog 
560046), and APC anti-CD25 (catalog 555434) were used to label Tregs (all antibodies used were obtained from 
BD Biosciences). To determine the expression of thyroid hormone receptors, we used Alexa Fluor 488 anti–thy-
roid hormone receptor β and FITC-thyroid hormone receptor alpha (Bioss Antibodies) and performed intra-
Figure 7. Thra1PV/+ mice are susceptible to Mtb infection. Six- to 8-week-old WT and Thra1PV/+ mice (both C57BL/6 background) (10 mice per group) were infect-
ed with approximately 100 CFUs of Mtb H37Rv by aerosol inhalation. (A) A schematic representation of the experiment is shown. (B) The P value for percent-
age survival was calculated using the log-rank test. The Kaplan-Meier survival curves of mice are shown. Data were pooled from 2 independent experiments 
(n = 5 mice in 2 experiments). (C) One month after infection, the bacterial burden in terms of CFUs in the lungs (n = 5 per group) was measured. Mean ± SD 
and P values are shown. The P values were derived using 1-way ANOVA with Tukey’s multiple-comparison test. (D) At 1 month after infection, lung homoge-
nates from uninfected control and Thra1PV/+ mice and Mtb-infected control and Thra1PV/+ mice (n = 4) were collected, and cytokine and chemokine levels were 
measured with multiplex ELISA. (E) The numbers of CD45+, CD4+, and Tregs (CD4+CD25+FoxP3+) in various immune cell populations were measured by flow 
cytometry. Mean ± SD and P values are shown. P values were derived using 1-way ANOVA with Tukey’s multiple-comparison test. (F) At 1 month after infec-
tion, lungs from uninfected control and Thra1PV/+ mice and those from Mtb-infected control and Mtb-infected Thra1PV/+ mice were isolated and formalin-fixed. 
Paraffin-embedded tissue sections were prepared, and H&E staining was performed. Total original magnification power = 10 ocular x 4 objective = 40 and 10 
ocular x 10 objective = 100.(G) Lung lesions were compared between groups. Data are representative of 2 independent experiments (n = 4 mice per group). P 
values were derived using 1-way ANOVA with Tukey’s multiple-comparison test. Data are expressed as the mean ± SD and P values are shown.
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cellular staining using an intracellular staining kit (BioLegend). In addition, we used PE anti–human GPR83 
(BioLegend) to determine the expression of glucocorticoid receptors.
Isolation and culture of  PBMCs. PBMCs were isolated by density gradient centrifugation using Ficoll-
Hypaque. Whole blood diluted with RPMI was layered over an equal volume of  Ficoll and centrifuged for 
30–40 minutes at 2000 RPM without braking. PBMCs were washed twice and counted by trypan blue stain-
ing. Freshly isolated PBMCs were cultured in 24-well plates at 1 × 106 cells/well in RPMI 1640 containing 
1% penicillin/streptomycin (Sigma-Aldrich), L-glutamine, and 10% heat-inactivated human serum with or 
without CFP-10 + ESAT-6 (10 μg/mL) at 37°C in a humidified atmosphere with 5% CO2. After 96 hours, 
cell-free culture supernatants were collected, aliquoted, and stored at –70°C until the cytokine concentrations 
were measured by ELISA according to the manufacturer’s guidelines.
Antigens for stimulation assays. For stimulation of  PBMCs, we used ESAT-6 and CFP-10 peptide pools 
(BEI Resources), consisting of  21 and 22 peptides covering the entire 6 kDa ESAT-6 and 10 kDa CFP-10 
protein sequence, respectively. A total of  1 × 106 human PBMCs were stimulated with and without 10 μg/
mL CFP-10 and ESAT-6 antigen and incubated at 37°C for 96 hours. For some experiments, freshly isolated 
PBMCs were cultured with or without γ-Mtb H37Rv (BEI Resources) (10 μg/mL) for 120 hours.
Flow cytometry. Briefly, a total of  1 × 106 PBMCs were stained for 3 cell subsets. T cells, monocytes, 
and the NK cell subsets were surface stained with respective antibodies and incubated in the dark for 30 
minutes before being analyzed by flow cytometry. To determine the FoxP3 population, we used an intra-
cellular staining kit from BioLegend. For surface staining, CD4 and CD25 were added to the cells before 
they were permeabilized. Anti-FoxP3 antibody was then added to the cells resuspended in staining buffer. 
After incubation, the cells were washed twice and fixed in 1% paraformaldehyde before acquisition on a 
FACSCalibur (BD Biosciences).
Gating strategies. CD4+ cells were identified after gating on the whole lymphocyte population. Tregs were gat-
ed as CD4+CD25+FoxP3+ cells. CD16-expressing CD56+ cells were identified as double-positive CD16+CD56+ 
cells. CD16-expressing monocytes were identified as CD14+CD16+ cells.
Measurement of  T3, T4, DHEA, and cortisol. T3, T4, DHEA, and cortisol concentrations in the serum were 
measured by ELISA by following the manufacturer’s instructions (T3 and T4, Meril Diagnostics) (DHEA 
and cortisone, Diagnostics Biochem Canada). Briefly, 25 μL of standards (positive controls provided by the 
manufacturer for the purpose of  assay) or patient sera were added to the respective precoated wells. Fifty 
microliters of  biotin and 100 μL of the enzyme conjugate were added to all the wells. The samples were 
incubated for 60 minutes at room temperature (RT). The wells were washed, and 100 μL of the substrate was 
added. The stop solution was added after 15–20 minutes of  incubation in the dark. The absorbance was read 
at 450 nm. The samples were run in batches, and assays were performed by commercial vendors who were 
blinded to the specimen status.
Measurement of  cytokine production. ESAT-6– and CFP-10–stimulated PBMCs as well as the T3-, T4-, 
DHEA-, and cortisol-treated H37Rv-infected MDM culture supernatants were stored at –70°C until the cyto-
kine concentrations were measured. In culture supernatants, the following 34 cytokines and chemokines were 
measured using a multiplex ELISA kit per the manufacturer’s instructions (34-Plex Human ProcartaPlex Pan-
el 1A, Thermo Fisher Scientific): Eotaxin/CCL11; GM-CSF; GRO-α/CXCL1; IFN-α; IFN-γ; IL-1β; IL-1α; 
IL-1RA; IL-2; IL-4; IL-5; IL-6; IL-7; IL-8/CXCL8; IL-9; IL-10; IL-12 p70; IL-13; IL-15; IL-17A; IL-18; IL-21; 
IL-22; IL-23; IL-27; IL-31; IP-10/CXCL10; MCP-1/CCL2; MIP-1α/CCL3; MIP-1β/CCL4; RANTES/
CCL5; SDF1-α/CXCL12; TNF-α; and TNF-β/LTA. The assay was run in batches by an independent reader 
blinded to the specimen status.
Determination of  Mtb H37Rv growth in MDMs. Monocytes were isolated from the PBMCs of healthy donors 
by magnetic beads conjugated to anti-CD14 (Miltenyi Biotec). CD14+ monocytes (0.5 × 106 cells/well) were 
plated in 24-well plates in 1 mL of antibiotic-free macrophage serum-free medium (SFM) (Gibco) and incu-
bated at 37°C in a humidified atmosphere in 5% CO2 for up to 6 days. The culture medium was renewed every 
day, and the cells were monitored morphologically for differentiation. After 6 days (after differentiation of the 
monocytes into macrophages), the cells were washed and infected with Mtb H37Rv at an MOI of 2.5 (1 MDM 
to 2.5 Mtb), incubated at 37°C for 2 hours, washed to remove the extracellular bacilli, and cultured in macro-
phage-SFM (Gibco). T3 (5, 10, and 15 nmol/L), T4 (50, 100, and 150 nmol/L), DHEA (200, 400, and 800 
μg/dl), and cortisol (200, 400, and 800 nmol/L) were added to some of the wells. Anti–IL-1α (10 ng/mL) was 
added to some of the wells. The cells were cultured for 120 hours. The supernatant was aspirated, and MDMs 
were lysed. The supernatant was centrifuged to pellet the bacteria, and the pellets were added to the cell lysates. 
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The bacterial suspensions were ultrasonically dispersed, serially diluted, and plated in triplicate on 7H10 agar. 
The number of colonies was counted after 3 weeks.
Confocal microscopy. Confocal microscopy was performed to determine IL-1α and TR-1 α/β expression 
on control or Mtb-infected monocytes in the presence or absence of  T4 hormone. The CD14+ monocytes 
(0.5 × 106 cells/well) were plated in 24-well plates in 1 mL of  antibiotic-free macrophage-SFM (Gibco) 
and incubated at 37°C in a humidified atmosphere with 5% CO2. After 2 hours, the cells were washed and 
infected with Mtb H37Rv at an MOI of  2.5 (1 MDM to 2.5 Mtb), incubated at 37°C for 2 hours, washed 
to remove the extracellular bacilli, and cultured in macrophage-SFM. T4 hormone was added to a few 
wells at a concentration of  150 nmol/L. For immunostaining, the cells were first washed briefly with PBS 
and fixed with 4% paraformaldehyde for 15–20 minutes at RT. The samples were then washed 3 times for 
5 minutes with PBST. Fixed cells were then incubated with 0.025% Triton X-100 in PBS (PBST) for 10 
minutes and subjected to 3 subsequent washes in PBST. Nonspecific binding was blocked by incubating 
the samples with 5% BSA in PBST for 1 hour and then washing 2 times for 5 minutes in PBST. The cells 
were then incubated at 4°C overnight in PBST with appropriate dilutions of  the primary antibodies IL-1α 
(1:250) and TR-1 α/β (1:250), and subsequently the cells were washed thoroughly for 3 times for 5 minutes 
in PBST. Next, the cells were stained with their respective secondary antibodies at 1:1000 dilutions (v/v), 
washed again with PBST for 3 times for 5 minutes, and mounted using FluoroShield mounting medium 
with DAPI. The mounted slides were then examined under a Zeiss LSM 510 meta laser scanning confocal 
microscope. ZEN 2009 software (Zeiss) was used for 3–5 image acquisitions per sample; then, the images 
were processed and uniformly quantified for each experiment using ImageJ software (NIH). Representative 
images are shown from 5 independent experiments.
Western blot. CD14+ monocytes were isolated from PBMCs of healthy volunteers and cultured at 1 × 106 
cells in 12-well plates to obtain MDMs for 2–3 days. MDMs were infected with Mtb H37Rv, and protein lysates 
were collected after 72 hours of infection using M-PER (mammalian protein extraction reagent) with prote-
ase and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Total protein concentrations were estimated 
using the bicinchoninic acid method, and 15 μg of protein samples were used to perform Western blotting. 
Resolved protein gels were electroblotted onto a PVDF membrane and blocked with 5% nonfat dry milk in 
TBST buffer for 1 hour at RT. Then, the membranes were probed with Rb-DIO1 (Invitrogen, PA5-100139; 
1:1000), goat-DIO2 (Novus, NBP1-00178; 1:1000), Rb-DIO3 (Novus, NBP1-05767; 1:1000), and Rb-GAPDH 
(Cell Signaling Technology, 2118; 1:1000) overnight at 4°C and followed by anti-rabbit (Cell Signaling Technol-
ogy, 7074; 1:10000) or anti-goat (Santa Cruz Biotechnology, sc-2354; 1:3000) HRP-linked secondary antibody 
for 1 hour at RT. Protein bands were detected using the enhanced chemiluminescence method using Bio-Rad 
ChemiDoc imaging system.
Statistical analysis used for human studies. Prism 7 software (GraphPad) was used for statistical analyses. 
Descriptive analyses were performed for all relevant variables prior to their inclusion in analyses. Frequen-
cy counts and percentages were obtained for interval and ordinal categorical data. For continuous variables, 
the central tendency (mean, mode, and median) and dispersion (range, variance, standard deviation, standard 
error, and coefficient of variation) were calculated. Possible outliers and/or influential observations were iden-
tified, and their validity was double-checked using available records. P values that were less than 0.05 were 
considered statistically significant. The results are expressed as the mean ± SD. For data that were normally 
distributed, comparisons between groups were assessed with ANOVA and 1-way repeated-measures ANOVA. 
When the overall ANOVA P values were statistically significant and post hoc tests were performed (t tests), 
P values were adjusted for multiple comparisons using Tukey’s multiple-comparison test. For data that were 
not normally distributed, Wilcoxon’s rank-sum test was used. The biomarker analysis program was used in 
MetaboAnalyst software to generate the ROC curves, and the AUC was determined for various hormones to 
predict the true TB progressors at baseline.
Human study approval. From June 2014 through June 2018, we enrolled 839 HHCs (Figure 1) aged 15–73 
years after obtaining written informed consent. The study was approved by the institutional ethics committees 
from BMMRC and BPHRC.
Mouse studies
Animals. Specific pathogen–free 4- to 8-week-old male and female WT C57BL/6 mice were obtained from 
The Jackson Laboratory, and Thra1PV/+ (C57BL/6 background) mice were provided in-house. Thra1PV/+ 
founder mice were back-crossed into the C57BL/6 background and maintained at the animal facility in the 
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University of  Texas Health Science Center at Tyler. Thra1PV/+ mice and littermates were genotyped (primers 
are listed in Supplemental Table 4) using the REDExtract-N-Amp Tissue PCR kit (MilliporeSigma) to con-
firm the presence of  the approximately 586-bp PCR product.
Aerosol infection of  mice with Mtb H37Rv. Before infecting the mice with Mtb H37Rv, bacteria were grown in 
liquid medium until the mid-log phase was reached and then frozen in aliquots at –70°C. Bacterial counts were 
determined by plating on 7H10 agar supplemented with oleic albumin dextrose catalase (OADC). For infec-
tion, bacterial stocks were diluted in 10 mL of normal saline (0.5 × 106 CFU/mL, 1 × 106 CFU/mL, 2 × 106 
CFU/mL, and 4 × 106 CFU/mL) and placed in a nebulizer within an aerosol exposure chamber that was cus-
tom-made by the University of Wisconsin. In preliminary studies, groups of 3 mice were exposed to the aerosol 
at each concentration for 15 minutes. After 24 hours, the mice were euthanized, and homogenized lungs were 
plated on 7H10 agar plates supplemented with OADC. CFUs were counted after 14–22 days of incubation at 
37°C. The concentration that deposited approximately 75–100 bacteria in the lung during aerosol infection was 
used for further studies (Supplemental Table 5).
Lung cell preparation. Lungs were harvested from the control and Mtb-infected WT C57BL/6 and Thra1PV/+ 
mice 30 days after Mtb challenge and were placed into 60 mm dishes containing 2 mL of HBSS. The tissues 
were minced with scissors into pieces no larger than 2–3 mm, and the fluid was discharged onto a 70 μm filter 
(BD Biosciences) that had been prewetted with 1 mL of PBS containing 0.5% BSA (Sigma-Aldrich) suspended 
over a 50-mL conical tube. The syringe plunger was then used to gently disrupt the lung tissue before washing the 
filter with 2 mL of cold PBS/0.5% BSA. The total number of viable cells in the lungs was determined with the 
trypan blue exclusion method. For flow cytometry experiments, we gated the total lung CD45+ cells (leukocytes) 
and measured various cell populations.
Flow cytometry and intracellular staining. After the mice were euthanized, lungs were perfused with 5 mL of  
PBS via the left ventricle. Lungs were mechanically homogenized and passed through a 70 μm cell strainer. 
Remaining RBCs were lysed using BD Pharm Lyse (BD Biosciences). Cells were treated with an Fc blocker 
(TruStain, BioLegend) prior to staining. Surface staining to identify leukocyte populations was then performed. 
For FoxP3 intracellular staining, cells were permeabilized with 0.1% saponin and stained for intracellular FoxP3. 
The cells were washed, resuspended in FACS buffer, and analyzed by using an Attune flow cytometer.
Multiplex ELISA. Mouse multiplex ELISA kits (36-Plex kits, Thermo Fisher Scientific) were used to measure 
chemokine and cytokine levels according to the manufacturer’s instructions.
Histopathology of  necrotic lesions in the lung. At the specified time points, mice were euthanized, and the har-
vested lungs were placed in 10% neutral buffered formalin (StatLab) for 48 hours to inactivate the infectious 
agent. Paraffin-embedded blocks were cut into 5 μm thick sections. For morphometric lesion analyses, the lung 
sections were stained with H&E and examined in a blinded manner to assess the necrotic lesions as previously 
described (72). Briefly, each lung lobe was quantified for the lesion area and percentage of lung lesions by using 
ImageJ (NIH). Two investigators, DT and RR, independently assessed the immunohistochemical readouts 
using morphometric analyses.
Statistics used for mouse studies. Prism 7 (GraphPad) was used for statistical analyses. The results are shown as 
the mean ± SEM. Comparisons between groups were performed by a paired or unpaired t test, as appropriate. 
Mouse survival was compared using the Kaplan-Meier log-rank test.
Mouse study approval. The IACUC of the University of Texas Health Science Center approved all the animal 
studies. Animal procedures involving the care and use of mice were performed in accordance with the guidelines 
of the NIH/OLAW (Office of Laboratory Animal Welfare).
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